Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Otto Carrs"'
Autor:
Laura J. V. Piddock, Richard Wise, Martin J. Blaser, David M. Livermore, Gail H. Cassell, Steven J. Projan, David Findlay, Kieran Hand, Frances Burke, Neil O. Fishman, Ragnar Norrby, Richard Bax, Stuart B. Levy, Roger Finch, Tony White, Chantal M. Morel, Otto Carrs, Robert Guidos, Michael J. Dawson, Marcus Keogh-Brown, Anthony R. White, Rick Davies, Ian Chopra, Glenn S. Tillotson, John H. Powers, Sarah Garner, Dominique L Monnet, Lloyd George Czaplewski
Publikováno v:
Journal of Antimicrobial Chemotherapy. 66:1948-1953
The original and successful business model of return on investment being sufficiently attractive to the pharmaceutical industry to encourage development of new antibacterial molecules and related diagnostics has been compromised by increasing develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d310dcbb5d76143cb6660bf6df04b695
https://doi.org/10.1093/jac/dkr260
https://doi.org/10.1093/jac/dkr260
Autor:
Michael J. Dawson, Martin J. Blaser, David Findlay, Neil Fishman, Stuart Levy, Sarah Garner, Rick Davies, Tony White, Marcus Keogh-Brown, Ian Chopra, Lloyd Czaplewski, John H. Powers, Steven J. Projan, Richard Wise, Roger Finch, Dominique Monnet, Ragnar Norrby, Laura J. V. Piddock, Kieran Hand, Robert Guidos, Chantal M. Morel, David M. Livermore, Frances Burke, Gail Cassell, Richard Bax, Otto Carrs, Glenn Tillotson
Publikováno v:
Journal of Antimicrobial Chemotherapy. 66:1945-1947
Regulatory agencies play a critical role in the licensing of new antimicrobial agents. To address the pivotal role played by regulatory agencies, particularly in the context of a paucity of new drugs active against bacteria resistant to currently ava
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d20d0a2474c53dc6cecad54797cf12e
https://doi.org/10.1093/jac/dkr259
https://doi.org/10.1093/jac/dkr259
Autor:
Roger Finch, David M. Livermore, Rick Davies, Frances Burke, Otto Carrs, Neil O. Fishman, John H. Powers, Richard Bax, Livermore David, David Findlay, Chantal M. Morel, Tony White, Gail H. Cassell, Richard Wise, Dominique L Monnet, Ragnar Norrby, Glenn S. Tillotson, Ian Chopra, Steven J. Projan, Robert Guidos, Stuart B. Levy, Marcus Keogh-Brown, Kieran Hand, Laura J. V. Piddock, Michael J. Dawson, Lloyd George Czaplewski, Martin J. Blaser, Sarah Garner
Publikováno v:
The Journal of antimicrobial chemotherapy. 66(9)
The dwindling supply of new antibiotics largely reflects regulatory and commercial challenges, but also a failure of discovery. In the 1990s the pharmaceutical industry abandoned its classical ways of seeking antibiotics and instead adopted a strateg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6abceb8bb2a5a10340a69d7305faa27
https://pubmed.ncbi.nlm.nih.gov/21700626
https://pubmed.ncbi.nlm.nih.gov/21700626
Autor:
Michael J. Dawson, Frances Burke, Chantal M. Morel, Marcus Keogh-Brown, Richard Wise, Robert Guidos, David Findlay, Neil Fishman, Steven J. Projan, Martin Blaser, John H. Powers, Otto Carrs, Roger Finch, Rick Davies, Tony White, Gail Cassell, Richard Bax, Stuart Levy, Glenn S. Tillotson, Laura J. V. Piddock, Kieran Hand, David Livermore, Ian Chopra, Ragnar Norrby, Lloyd George Czaplewski, Sarah Garner, Dominique Monnet
Publikováno v:
Journal of Antimicrobial Chemotherapy. 66:1939-1940
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8130f0e382ba601e33f1547fabcd3a87
https://doi.org/10.1093/jac/dkr261
https://doi.org/10.1093/jac/dkr261